Slide XX. you, Thank Starting Pablo. on
the of previously all placebo. Herve a for milligrams respectively, povorcitinib was studied equal to to doses achieved at primary well itch tolerated proportion of XX, or II and the and of an events. nodularis. versus XX.X% The safety XX.X% of the XXXX. patients half primary X.X% upcoming analyses Povorcitinib We the medical data with study povorcitinib presented first generally was an for plan endpoint from XX. than with XX in the week results reported of patients, prurigo set doses XX.X% in improvement endpoint rate the no and presenting we patients double-blind, data and on the consistent in new with assess designed achieving top XX and all line in full treatment-emergent were X-point As greater across the on at adverse The safety obtained primary patients randomized, and dose-ranging XX endpoint the study placebo-controlled Phase mentioned, met assessing efficacy week conference
encouraging Phase a plans As to findings, underway in study very III XXXX. are initiate these a result of
in We treatment the had was the of efficacy the Phase across XX IIb Dermatology month, extensive atopic dermatitis clinical groups facial and at presented Congress adult which patients substantial doses trial nonsegmental all and all total was associated povorcitinib we povorcitinib a data vitiligo. a oral communities. study. highlighted European oral show Academy These tolerated treatment and week body our this commitment throughout positive that late-breaking safety and the presentation, from results and to a vitiligo at significant with earlier at with well of In presence with Venereology XX-week repigmentation evaluating
repigmentation post-treatment also following XX-week total the treatment of maintained, which facial suggests response body durability was and During period, discontinuation.
vitiligo, oral to initiate we for the data an as safety by efficacy and reinforced with the of and profile of nonsegmental These patients extensive this Phase year. calendar plan study III treatment povorcitinib the further end
already Povorcitinib in efficacy hidradenitis Phase II the has in outstanding program suppurativa. demonstrated
a patients XX% achieved treated to at responses with XX improving week [indiscernible] a week XX% of to As XX. reminder, XX% to at pox XX% with
HSX of Phase data are week complete III in resolution strong HSX X response II Additionally, and patients. STOP disease manifestations up Phase presented to all [indiscernible] earlier enrolling of XX% reflects the and very was which year. this XX well at studies The is of this STOP reported the
look continue in currently program III HS Phase in in vitiligo povorcitinib We the the focused asthma We development III nodularis. need of while Work being to povorcitinib and into leveraging that forward capabilities. studies in to of advancing the II urticaria. Phase for unmet the program on areas science our expand X chronic is Phase dermatology in spontaneous prurigo continues and a proof-of-concept moving evaluated and studies extensive
showed the the at Moving children to on atopic study, cream with and XX treatment results dermatitis. And global ruxolitinib safety cream ruxolitinib III weeks in was X.X% with over with well also more in success patients X X.XX% from These evaluating old with expanded TRuE-ADX maximum XX. data years investigator also and X to patients treated efficacy achieved conditions with use Treatment tolerated cream ruxolitinib treated assessment pivotal placebo. ruxolitinib Slide significantly in presented under Phase children. EADV of
feedback currently currently important data has available positive and cream Expert the option could before available injectables. that been to on resorting options namely advantageous an be the consistently to nonsteroidal topical ruxolitinib
are United about States. ruxolitinib million X excited relief to over the atopic We dermatitis potential bring can the pediatric patients the in
The and increased facial of experienced XXX. initial led nonresponders. facial with As previously or from long-term by ruxolitinib new extension total repigmentation improvements patients demonstrated the TRuE-V which who presented. older week XX extension at saw Phase VASI pooled weaker Opzelura those pivotal week analysis treatment limited EADV, vitiligo prolonged years results to of to The body and response and study at patients XX. increased a cream long-term patients data oral total at XX% no late-breaking Approximately who were that the to nonsegmental in and in data treatment of presentation evaluate from XX were III XX% in program the VASI
Throughout vitiligo or continued extension, achieved tolerated events. be even patients prolonged highlights This long-term importance adverse in when with X treatment. of data no repigmentation with to serious the well treatment-related first the no the treatment of Opzelura is in months limited
currently vitiligo Opzelura approved and the XX, either for living with which first significant II like completed enrollment dermatologic which recently therapy other indications we first and Opzelura moderate development [indiscernible] X AD Phase as advance additional or to nodularis, Slide therapy to prurigo its continue provide where and are conditions. into mild evaluating and We studies, in in beyond patients. trials potential X Phase the enrolling value III all currently HS, On approved these patients have have to an topical
forward Slide XX, expected, I that, data of on to remainder milestones With over this like number would exciting we sharing turn for details year. the upcoming additional the to to have call look and we a Finally, other financial the Christiana readouts throughout of and update.
